<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457312</url>
  </required_header>
  <id_info>
    <org_study_id>UW 12-077</org_study_id>
    <nct_id>NCT02457312</nct_id>
  </id_info>
  <brief_title>The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues</brief_title>
  <official_title>The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at studying the effect of letrozole in early pregnancy in placenta and&#xD;
      decidua including the progesterone receptor and the apoptotic factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty healthy subjects requesting legal surgical abortion up to 63 days gestation will be&#xD;
      recruited for this study. They will be randomized to receive either placebo tablets or&#xD;
      letrozole 10 mg daily for 7 days before suction evacuation. Suction evacuates which include&#xD;
      the placenta and some decidua collected by the procedure in these 20 subjects will be used&#xD;
      for the laboratory studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The expression of progesterone receptors and apoptotic factors in the placental and decidual cells by immunostaining.</measure>
    <time_frame>8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apoptosis in the placental and decidual cells as demonstrated by TUNEL assay.</measure>
    <time_frame>8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Letrozole group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Letrozole 10 mg daily for 7 days before suction evacuation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets (look identical to letrozole tablets) daily for 7 days before suction evacuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>letrozole 10 mg daily for 7 days before suction evacuation</description>
    <arm_group_label>Letrozole group</arm_group_label>
    <other_name>Letrozole group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The gestational age should be up to 63 days. An ultrasound assessment would be&#xD;
             performed to confirm the gestation.&#xD;
&#xD;
          -  The woman is willing and able to participate after the study has been explained&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Criteria for prospective exclusion&#xD;
&#xD;
        Any indication of past or present ill health will be considered a contraindication for&#xD;
        recruitment to the study. In particular, subjects should not be recruited if any of the&#xD;
        following conditions is present:&#xD;
&#xD;
          1. multiple pregnancies&#xD;
&#xD;
          2. uterine fibroids&#xD;
&#xD;
          3. any significant medical disorder&#xD;
&#xD;
          4. intrauterine contraceptive device in situ&#xD;
&#xD;
          5. contra-indications to the use of letrozole or misoprostol&#xD;
&#xD;
               -  Criteria for exclusion from a secondary analysis&#xD;
&#xD;
        Situation in which subjects who have been formally admitted to the study could be excluded&#xD;
        from a secondary analysis include:&#xD;
&#xD;
          1. the use of drugs other than those prescribed by the investigator for the treatment of&#xD;
             possible therapy-related side-effects especially drugs with prostaglandin synthetase&#xD;
             inhibitory activity such as salicylates, indomethacin or mefenamic acid&#xD;
&#xD;
          2. any violation of the study protocol&#xD;
&#xD;
          3. essential data missing from the subject's records making it impossible to judge the&#xD;
             treatment outcome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivian CY Lee, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>May 27, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary Hospital, Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Lee Chi Yan Vivian</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

